Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Tocagen Inc. (NASDAQ: TOCA).

Full DD Report for TOCA

You must become a subscriber to view this report.


Recent News from (NASDAQ: TOCA)

Tocagen to Participate in Investor Conferences in November
SAN DIEGO , Nov. 7, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall , chief executive officer, will present at the following upcoming investor conferences: Wednesday, November ...
Source: PR Newswire
Date: November, 07 2018 16:01
Tocagen to Present Updated Data from Clinical and Preclinical Studies at Three Scientific and Medical Conferences
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA ), a clinical-stage, cancer-selective gene therapy company, today announced three presentations of updated clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual Meeting &am...
Source: PR Newswire
Date: November, 06 2018 08:00
Tocagen to Report Third Quarter 2018 Financial Results on Thursday, November 8
SAN DIEGO , Nov. 1, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2018 financial results and business progress on Thursday, November 8, 2018, after the close of the U....
Source: PR Newswire
Date: November, 01 2018 16:01
Your Cancer Highlight: Tocagen Moves To Finish Up A Trial Long In The Making
In oncology, there are a few forms of cancer that get regarded for their grave prognoses. Not that you ever want to get any kind of cancer, but certain tumors have been particularly resistant to treatment advances over the years. Glioblastoma is a hallmark of this class of "difficult-to-treat"...
Source: SeekingAlpha
Date: September, 20 2018 08:00
Tocagen Announces Early Completion of Enrollment in Toca 5 Pivotal Phase 3 Brain Cancer Trial
SAN DIEGO , Sept. 19, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that it has completed the planned enrollment of 380 patients in the global Toca 5 pivotal Phase 3 trial approximately three months ahead of sc...
Source: PR Newswire
Date: September, 19 2018 08:00
Premarket analyst action - healthcare
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $11 (80% upside) price target at SunTrust. Shares up  2%  premarket. More news on: Adverum Biotechnologies, Inc., Glaukos, Tocagen Inc, Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 30 2018 08:26
Tocagen to Participate in Two Investor Conferences Next Week
SAN DIEGO , Aug. 28, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall , chief executive officer, will participate in a panel discussion titled, "Chinese Capital Meets Western Innovation" on...
Source: PR Newswire
Date: August, 28 2018 16:05
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis
SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the Toca 5 pivotal Phase 3 trial continues without modification following a planned first interim analysis of data conducted by an Independent ...
Source: PR Newswire
Date: August, 23 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1412.2512.0812.4912.00229,702

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-115,43013,78039.4049Short
2018-12-104,92123,46420.9726Cover
2018-12-073,4378,59040.0116Short
2018-12-0612,60651,69124.3872Cover
2018-12-0418,60363,38329.3501Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TOCA.


About Tocagen Inc. (NASDAQ: TOCA)

Logo for Tocagen Inc. (NASDAQ: TOCA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $187,965,655 - 05/18/2018
  • Issue and Outstanding: 19,911,616 - 02/28/2018

 


Recent Filings from (NASDAQ: TOCA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 23 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: May, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018

 

 


Daily Technical Chart for (NASDAQ: TOCA)

Daily Technical Chart for (NASDAQ: TOCA)


Stay tuned for daily updates and more on (NASDAQ: TOCA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TOCA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TOCA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TOCA and does not buy, sell, or trade any shares of TOCA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/